Sunday November 22 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Astex Technology Limited

Astex Technology is a structure-based drug discovery company pioneering the use of high throughput X-ray crystallography for the rapid identification of novel drug candidates. The company's unique structural screening approach utilizes protein crystal structures to detect the binding of drug fragments, which are then optimized into potent lead compounds. Facilitating this approach is the company's integrated drug discovery platform of HTX* technologies, which covers all aspects of structure-based research, including protein production, crystallization, structure determination, bioinformatics and computational and medicinal chemistry. Astex is focusing its drug discovery approaches on protein targets from families and/or pathways, including validated kinases, phosphatases and proteases implicated in human disease. Astex has two research agreements with Janssen Research Foundation, a division of Johnson & Johnson, and a cytochrome P450 structural biology research agreement with AstraZeneca AB.


Contact Details:
250 Cambridge Science Park, Milton Road
Cambridge
CBW OWE
United Kingdom
Tel:+44 (0) 1223 22 62 00
Fax:+44 (0) 1223 22 62 01
Email:t.haines@astex-technology.com
WWW:

www.Astex-Technology.com/




Loading...

Recent Publications by Astex Technology Limited:

Prediction of binding modes for ligands in the cytochromes P450 and other heme-containing proteins.
The cytochromes P450 (P450s) are a family of heme-containing monooxygenase...
13th June, 2006
Astex Technology, Cambridge, United Kingdom. Proteins. 2005 Mar 1;58(4):836-44.
DOI Direct Link
Structural biology and drug discovery.
It has long been recognized that knowledge of the 3D structures of...
25th May, 2006
Astex Technology, 436 Cambridge Science Park, Milton Road, Cambridge CB4 Drug Discov Today. 2005 Jul 1;10(13):895-907.
DOI Direct Link
Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.
Since the discovery that activating mutations of the Ras GTPase were...
25th May, 2006
Astex Technology Ltd, 436 Cambridge Science Park, Milton Rd, Cambridge CB4 Curr Opin Pharmacol. 2005 Aug;5(4):350-6.
DOI Direct Link
Fragment-based lead discovery: leads by design.
Fragment-based lead discovery (also referred to as needles, shapes,...
20th April, 2006
Astex Technology, 436 Cambridge Science Park, Milton Road, Cambridge CB4 Drug Discov Today. 2005 Jul 15;10(14):987-92.
DOI Direct Link
The design of a new potent and selective ligand for the orphan bombesin receptor subtype 3 (BRS3).
Extensive SAR studies on the unselective BRS3 agonist,...
8th November, 2005
Astex J Pept Sci. 2005 Mar;11(3):136-41.
DOI Direct Link

View more Astex Technology Limited research publications.

Astex Technology Limited Patents:

US Patent No.Title
6546074 Protein crystal structure and method for identifying protein modulators
6484103 Crystal structure

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 359 times since April 2007, the link to the organisation's website has been followed 63 times

Search for more companies in Cambridge

Search for more companies in



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Astex Technology Limited

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.